

Fisher Broyles

Name: Suzanne Nguyen, Ph.D.

Email: suzanne.nguyen@fisherbroyles.com

Direct: +1.774.284.6644

Office: Boston

Practice Areas: Intellectual Property; Patent Prosecution

Bar Admissions: Massachusetts; United States Patent and Trademark Office

Education: Boston University School of Law, J.D. 2020; Massachusetts Institute of Technology, Ph.D 2007; California Institute of Technology, B.S. 1996

Experience: Goodwin Procter LLP; McDermott Will & Emery LLP; Choate Hall and Stewart LLP

Suzanne Nguyen provides strategic intellectual property advice particularly for early-stage life sciences companies and life sciences investors. Dr. Nguyen helps companies build and grow their patent portfolios and supports them during financing and transactions. Dr. Nguyen's experience covers a wide array of technologies, including peptide or antibody-based therapeutics, radiopharmaceuticals, gene therapy, gene editing, epigenetics, immuno-oncology, cell therapies, and diagnostics.

Dr. Nguyen has been working in the field of intellectual property since 2007, beginning her career as a scientific advisor and then as a patent agent at another law firm. Dr. Nguyen also has previous in-house experience at a Swedish healthcare company.

Corporate Experience

- Molnlycke Health Care AB - Global Patent Advisor

Representative Transactions

- Advised biotech venture capital firm on IP due diligence matters in connection with new life sciences company formations
- Represented biotechnology company in intellectual property matters relating to antibody and antibody-drug conjugate therapeutics
- Represented non-profit research institute on intellectual property matters relating to stem cells, cell generation, and screening systems

- Assisted in IP due diligence on behalf of a biotech venture capital firm in connection with a Series A financing of a clinical-stage company developing antibody-drug conjugates to treat cancer
- Represented biotech company developing radioimmunoconjugates in intellectual property matters including during the company's acquisition by a pharmaceutical company
- Represented a biotech company developing gene editing-based therapies in intellectual property matters and assisted on matters in connection with their Initial Public Offering
- Represented a biotech company in intellectual property matters related to peptide-based pharmaceuticals for ophthalmology indications
- Represented life sciences venture creation firm in intellectual property matters, including in connection with the formation of a company developing epigenomic controllers for therapeutic purposes
- Represented biotech company developing small molecule therapeutic for eye disorders in intellectual property matters including during the company's acquisition by a pharmaceutical company
- Represented biotech company developing oncolytic viral therapies in intellectual property matters including in connection with investment by pharmaceutical company
- Assisted in successfully defending a pharmaceutical company's enzyme replacement therapy patent in an Inter Partes Review proceeding
- Represented a venture-backed startup using synthetic biology and machine learning to develop therapies and vaccines in intellectual property matters

Presentations & Teaching Experience

- "Innovating with AI in the life sciences," presented at the Swedish American Chamber of Commerce, New England event "In the forefront of AI and Entrepreneurship," Boston, MA, December 2024
- "Managing US Patent Prosecution from Abroad," Global Patent Congress, Copenhagen, September 2014
- "Developments in US Patent Law," Nordic Intellectual Property Rights Conference, Stockholm, March 2014

Publications

- Author, "What Young Inventors Need to Know about Patents," Imagine Magazine (published by Johns Hopkins University Center for Talented Youth), February 2014
- Co-Author, "Ablation of de novo DNA methyltransferase Dnmt3a in the nervous system leads to neuromuscular defects and shortened lifespan," Developmental Dynamics, June 2007

- Co-Author, "Suppression of Intestinal Neoplasia by Deletion of Dnmt3b," Molecular and Cell Biology, 26(8): 2976-2983, April 2006
- Author, "Developmental Biology: A Field in Depth," Imagine Magazine, December 2002
- Co-Author, "A Critical Role for Dnmt1 and DNA Methylation in T Cell Development, Function, and Survival," Immunity, 15(5): 763-774, November 2001
- Co-Author, "Requirement of Shp-2 Tyrosine Phosphatase in Lymphoid and Hematopoietic Cell Development," Blood, 97(4): 911-914, February 2001
- Co-Author, "Promoter Element for Transcription of Unrearranged T-Cell Receptor Beta-Chain Gene in Pro-T Cells," Blood, 93(9): 3017-3025, May 1999

Awards and Recognitions

- Selected for inclusion in the Massachusetts Rising Stars list by Super Lawyers (2023-2026)